CN104507930B - 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物 - Google Patents

作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物 Download PDF

Info

Publication number
CN104507930B
CN104507930B CN201380038959.8A CN201380038959A CN104507930B CN 104507930 B CN104507930 B CN 104507930B CN 201380038959 A CN201380038959 A CN 201380038959A CN 104507930 B CN104507930 B CN 104507930B
Authority
CN
China
Prior art keywords
phenyl
dihydro
compound
oxo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380038959.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104507930A (zh
Inventor
胡邵京
王飞
许志国
王燕萍
王印祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Priority to CN201380038959.8A priority Critical patent/CN104507930B/zh
Publication of CN104507930A publication Critical patent/CN104507930A/zh
Application granted granted Critical
Publication of CN104507930B publication Critical patent/CN104507930B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201380038959.8A 2012-06-29 2013-07-01 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物 Expired - Fee Related CN104507930B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380038959.8A CN104507930B (zh) 2012-06-29 2013-07-01 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/077924 2012-06-29
CN2012077924 2012-06-29
CN201380038959.8A CN104507930B (zh) 2012-06-29 2013-07-01 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
PCT/CN2013/078592 WO2014000713A1 (en) 2012-06-29 2013-07-01 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
CN104507930A CN104507930A (zh) 2015-04-08
CN104507930B true CN104507930B (zh) 2017-10-10

Family

ID=49782283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380038959.8A Expired - Fee Related CN104507930B (zh) 2012-06-29 2013-07-01 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物

Country Status (15)

Country Link
US (1) US9617257B2 (enExample)
EP (1) EP2867223B1 (enExample)
JP (1) JP6059342B2 (enExample)
KR (3) KR101726522B1 (enExample)
CN (1) CN104507930B (enExample)
AU (1) AU2013283993B2 (enExample)
BR (1) BR112014032745B1 (enExample)
CA (1) CA2878049C (enExample)
ES (1) ES2698511T3 (enExample)
IN (1) IN2015DN00372A (enExample)
RU (1) RU2619130C2 (enExample)
SG (1) SG11201408750VA (enExample)
TW (1) TWI520962B (enExample)
WO (1) WO2014000713A1 (enExample)
ZA (1) ZA201500344B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
ES2769124T3 (es) * 2015-07-20 2020-06-24 Betta Pharmaceuticals Co Ltd Forma cristalina de maleato de derivados de piridina condensados y usos de la misma
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
WO2018215668A1 (en) * 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
JP7131837B2 (ja) * 2017-06-19 2022-09-06 アビスコ セラピューティクス カンパニー リミテッド Ｃｓｆ－１ｒ阻害活性を有するアザアリール誘導体、その製造方法および応用
CN109988108B (zh) * 2017-12-29 2022-04-29 江苏豪森药业集团有限公司 一种卡博替尼的制备方法
WO2020124060A1 (en) 2018-12-14 2020-06-18 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112225748B (zh) * 2020-10-20 2021-11-30 四川大学华西医院 一种具有flt3激酶抑制活性的小分子化合物及其应用
TWI812301B (zh) * 2021-06-24 2023-08-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060318A2 (en) * 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
WO2006116713A1 (en) * 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
CN101248080A (zh) * 2005-05-20 2008-08-20 梅赛尔基因股份有限公司 Vegf受体和hgf受体信号的抑制剂
US20080312270A1 (en) * 2007-05-02 2008-12-18 Matthew Brown Compounds and methods useful for treating asthma and allergic inflammation
CN102086211A (zh) * 2009-12-08 2011-06-08 深圳市东阳光实业发展有限公司 作为蛋白激酶抑制剂的芳杂环化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005389A2 (en) * 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
US20100016307A1 (en) * 2006-10-27 2010-01-21 Toshihiro Hamajima Novel compounds
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
SG187064A1 (en) * 2010-07-14 2013-02-28 Zhejiang Beta Pharma Inc NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060318A2 (en) * 2004-11-30 2006-06-08 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
WO2006116713A1 (en) * 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
CN101248080A (zh) * 2005-05-20 2008-08-20 梅赛尔基因股份有限公司 Vegf受体和hgf受体信号的抑制剂
US20080312270A1 (en) * 2007-05-02 2008-12-18 Matthew Brown Compounds and methods useful for treating asthma and allergic inflammation
CN102086211A (zh) * 2009-12-08 2011-06-08 深圳市东阳光实业发展有限公司 作为蛋白激酶抑制剂的芳杂环化合物

Also Published As

Publication number Publication date
KR20150031320A (ko) 2015-03-23
RU2015102057A (ru) 2016-08-20
KR20170017014A (ko) 2017-02-14
EP2867223A4 (en) 2016-01-06
IN2015DN00372A (enExample) 2015-06-12
KR101726522B1 (ko) 2017-04-12
SG11201408750VA (en) 2015-01-29
TW201418254A (zh) 2014-05-16
JP2015521634A (ja) 2015-07-30
US9617257B2 (en) 2017-04-11
EP2867223B1 (en) 2018-09-05
CA2878049C (en) 2016-12-13
ZA201500344B (en) 2016-08-31
RU2619130C2 (ru) 2017-05-12
CN104507930A (zh) 2015-04-08
KR101726555B1 (ko) 2017-04-12
EP2867223A1 (en) 2015-05-06
TWI520962B (zh) 2016-02-11
BR112014032745A2 (pt) 2017-06-27
JP6059342B2 (ja) 2017-01-11
KR20170017015A (ko) 2017-02-14
HK1207642A1 (en) 2016-02-05
US20150315210A1 (en) 2015-11-05
BR112014032745B1 (pt) 2022-01-04
WO2014000713A1 (en) 2014-01-03
ES2698511T3 (es) 2019-02-05
CA2878049A1 (en) 2014-01-03
AU2013283993B2 (en) 2016-07-07
AU2013283993A1 (en) 2015-02-05
KR101770545B1 (ko) 2017-08-22

Similar Documents

Publication Publication Date Title
TWI520962B (zh) As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
KR101538707B1 (ko) c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체
JP2023536948A (ja) Ｅｇｆｒ阻害剤およびその製造方法と応用
JP7366996B2 (ja) 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤
BRPI0608160A2 (pt) anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
ES2945573T3 (es) Compuesto de dioxazolina, método de preparación y usos del mismo
JP6646044B2 (ja) キナーゼ阻害剤としての化合物および組成物
CA2990583A1 (en) 1,4-disubstituted imidazole derivative
EP3845527A1 (en) Multi-substituted pyridone derivatives and medical use thereof
KR20220007111A (ko) 키나아제 억제제로 사용되는 화합물 및 이의 응용
WO2025034951A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors
CN115836064B (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
RU2668074C2 (ru) Конденсированные пятичленные гетероциклические пиридиновые соединения, способ их производства и применение
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用
HK1207642B (en) Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors
CN119013283A (zh) 大环egfr抑制剂及其制备方法和药学上的应用
WO2026033475A1 (en) Substituted aryl or heteroaryl compound derivatives and pharmaceutical use thereof
EP4036086A1 (en) Heterocyclic derivative and use thereof
HK40056078A (en) Multi-substituted pyridone derivatives and medical use thereof
JP2025526717A (ja) ＴＧＦ－β阻害剤化合物及びその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207642

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1207642

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171010

CF01 Termination of patent right due to non-payment of annual fee